（来源：一度医药） 具体到畅销药品，Ocrevus上半年销售额35.06亿瑞士法郎，增长8%，其中美国市场贡献24.62亿瑞士法 郎，占其总销售额的70%以上；Hemlibra销售额24.21亿瑞士法郎，增长17%，国际市场（除美、欧、日 外）增速达66%；Vabysmo销售额20.67亿瑞士法郎，增长18%，欧洲市场和日本市场分别增长33%和 31%。此外，Xolair表现尤为亮眼，销售额14.45亿瑞士法郎，同比增长34%，且全部来自美国市场； Phesgo以55%的增速成为乳腺癌领域的黑马，销售额达11.97亿瑞士法郎，国际市场销售额增长182%。 | Top 20 best-selling | Total | | United | | Europe | | Japan | | International | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | pharmaceuticals | | | States | | | | | | | | | | CHF m | % | CHF m % | | CHF ...

Core Insights - AbbVie's RINVOQ (upadacitinib) has received FDA approval for the treatment of giant cell arteritis, marking it as the first oral JAK inhibitor approved for this condition in Western countries, and the ninth indication for the drug [1][6] Group 1: Market Dynamics - The approval of RINVOQ has intensified competition among pharmaceutical companies in the giant cell arteritis market [1] - DelveInsight estimates the giant cell arteritis market size to grow from USD 960 million in 2023 at a significant CAGR by 2034, driven by factors such as an increasing geriatric population and rising prevalence of cardiovascular disorders [14] Group 2: Treatment Landscape - The primary treatment for giant cell arteritis has traditionally involved high doses of corticosteroids like prednisone, with the aim of preventing serious complications such as blindness [3] - ACTEMRA/ROACTEMRA (tocilizumab) was the first approved treatment for giant cell arteritis in Europe, with its approval supported by the Phase III GiACTA study demonstrating improved remission rates [4][7] - RINVOQ's pivotal Phase 3 SELECT-GCA trial showed that 46.4% of patients achieved sustained remission with RINVOQ compared to 29.0% on placebo [7] Group 3: Emerging Therapies - Companies like Novartis and CSL/Kiniksa Pharmaceuticals are conducting clinical trials for new treatment options, indicating a need for more effective therapies in the giant cell arteritis space [10][12] - The anticipated launch of emerging therapies is expected to transform the market landscape, offering new standards of care and opportunities for innovation [13]